INS and Alzheimer disease: At this moment, there are ten ongoing unpublished clinical trials accessing intranasal insulin beneficial effects on AD patients (NCT00581867, NCT02010476, NCT01436045, NCT01636596, NCT03038282, NCT01767909, NCT00018382, NCT01595646, NCT01547169, NCT02462161).